1. Volume 10, Issue 4, Pages 351-369 (April 2009)
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England 
Bernard Rachet, MD, Camille Maringe, MSc, Ula Nur, PhD, Manuela Quaresma, MSc, Anjali Shah, PhD, Laura M Woods, PhD, Libby Ellis, MPH, Sarah Walters, MSc, Prof David Forman, PhD, John Steward, FFPH, Prof Michel P Coleman, FFPH 
The Lancet Oncology 
Volume 10, Issue 4, Pages (April 2009)
DOI: /S (09)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1
Structure of survival analyses in relation to NHS cancer plan, patients diagnosed 1996–2006 and followed up to 2007
Numbers in the cells indicate the minimum number of years of follow-up completed by patients surviving to the end of a given calendar year (columns) who were diagnosed in the index year (rows). In the cohort approach all patients diagnosed in a given period were followed up for at least 5 years. In the complete approach some patients were followed up for less than 5 years. In the hybrid approach survival is estimated from the most recent follow-up data (dashed lines). Conditional 5-year survival is restricted to those who had survived at least 1 year; ie, excluding follow-up in shaded cells.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2
3-year relative survival (%) for adults diagnosed with 21 common cancers during 1996–2000 and 2004–06 in England and Wales
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Funnel plots of 1-year relative survival (%) and year-on-year trend (%) during 2004–06: selected cancers, by sex, in the nine government office regions of England, and Wales
All patients were adults aged 15–99 years, and were diagnosed during 2004–06. A=North East. B=North West. D=Yorkshire and the Humber. E=East Midlands. F=West Midlands. G=East of England. H=London. J=South East. K=South West. W=Wales. Control limits are shown by coloured curves: the inner limits are for 95%, the outer limits are for 99·8%.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions